ACR Convergence 2023| ANCA-Associated Vasculitis| Psoriatic Arthritis

An official publication of the ACR and the ARP serving rheumatologists and rheumatolgy professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • ACR Open Rheumatology
    • Arthritis & Rheumatology
    • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: tocilizumab

Tocilizumab Promising for the Treatment of Polymyalgia Rheumatica

Michele B. Kaufman, PharmD, BCGP  |  January 1, 2022

In a study, patients with new-onset polymyalgia rheumatica (PMR) who were treated with subcutaneous tocilizumab were more likely to achieve sustained, glucocorticoid-free remission than patients who received placebo.

Filed under:ACR ConvergenceDrug UpdatesMeeting Reports

Does Switching from IV to Subcutaneous Tocilizumab Affect RA Disease Flare?

Michele B. Kaufman, PharmD, BCGP  |  December 9, 2021

Researcher identified multiple factors for flare, including non-use of methotrexate, in patients with rheumatoid arthritis who had switched from intravenous (IV) tocilizumab to subcutaneous tocilizumab.

Filed under:ACR ConvergenceDrug UpdatesMeeting Reports Tagged with:ACR Convergence 2021ACR Convergence 2021 – RAIV tocilizumabRA flaressubcutaneous tocilizumabtocilizumab

Tocilizumab Effective for Early SSc-Associated Interstitial Lung Disease

Lara C. Pullen, PhD  |  September 22, 2021

Treatment with tocilizimab preserved lung function in patients with systemic sclerosis (SSc) and interstitial lung disease (ILD) regardless of a patient’s level of lung involvement, according to a recent study.

Filed under:Conditions Tagged with:interstitial lung disease (ILD)systemic sclerosis (SSc)systemic sclerosis-associated ILDtocilizumab

ACR Guidance on Tocilizumab Allocation During Shortage

From the College  |  September 1, 2021

In June, the U.S. Food & Drug Administration (FDA) issued an emergency use authorization (EUA) for tocilizumab (Actemra) for treatment of hospitalized COVID-19 adults and children who are receiving systemic corticosteroids and supplemental oxygen. Since this announcement, the tocilizumab manufacturer, Genentech, has not been able to produce enough product to meet the higher demand. The…

Filed under:Drug UpdatesLegislation & Advocacy Tagged with:COVID-19Drug shortagetocilizumab

EU Evaluates Tocilizumab as COVID-19 Treatment

Reuters Staff  |  August 18, 2021

(Reuters)—Europe’s drugs regulator said on Monday it was evaluating the use of Roche’s arthritis drug, tocilizumab, in hospitalized adults with severe COVID-19, its latest review of a potential coronavirus treatment. Tocilizumab, sold by Roche as Actemra and RoActemra, has shown promise in clinical trials in treating COVID-19, and was approved by U.S. health regulators in…

Filed under:Drug Updates Tagged with:COVID-19European UnionInternationaltocilizumab

ACR Update on Tocilizumab Shortages

From the College  |  August 17, 2021

ATLANTA—The ACR is actively engaged with the U.S. Food & Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) drug shortage team as they work with the manufacturer to resolve current shortages of tocilizumab (Actemra). Demand for tocilizumab has outpaced supply, with demand increasing after the FDA’s June 24 Emergency Use Authorization (EUA) for…

Filed under:Drug UpdatesFrom the College Tagged with:Drug shortageIV tocilizumabtocilizumabU.S. Food and Drug Administration (FDA)

Efficacy of Tocilizumab Monotherapy After Ultra-Short Glucocorticoid Administration in GCA

Michele B. Kaufman, PharmD, BCGP  |  July 27, 2021

In a small study, patients with GCA maintained remission after receiving three days of treatment with methylprednisolone followed by tocilizumab.

Filed under:Drug UpdatesMeeting ReportsVasculitis Tagged with:EULARGCAgiant cell arteritis (GCA)GlucocorticoidsmonotherapyRemissiontocilizumab

Tocilizumab After Ultra-Short Course Steroids Promising for Newly Diagnosed GCA

Marilynn Larkin  |  July 15, 2021

NEW YORK (Reuters Health)—Tocilizumab induced a slow and lasting remission after an ultra-short pulse (three days) of steroids in newly diagnosed giant cell arteritis (GCA) patients, a proof-of-concept trial shows.1 His early research on cytokines and glucocorticoids led Peter Villiger, MD, of Medical Center Monbijou, Bern, Switzerland, to find ways to reduce steroid use, he…

Filed under:ConditionsDrug UpdatesVasculitis Tagged with:GCAgiant cell arteritis (GCA)IV tocilizumabSteroidstocilizumab

FDA Approves Tocilizumab to Treat Systemic Sclerosis-Associated ILD

Michele B. Kaufman, PharmD, BCGP  |  March 25, 2021

Subcutaneous tocilizumab is the first biologic agent approved by the FDA treat patients with systemic sclerosis-associated interstitial lung disease.

Filed under:Drug Updates Tagged with:FDAFDA approvalILDinterstitial lung disease (ILD)systemic sclerosis (SSc)systemic sclerosis-associated ILDtocilizumabU.S. Food and Drug Administration (FDA)

Tocilizumab Fails Late-Stage Trial for COVID-19

John Revill  |  July 29, 2020

ZURICH (Reuters)—Roche’s attempt to retool its rheumatoid arthritis drug Actemra/RoActemra (tocilizumab) to treat patients hospitalized with severe COVID-19-related pneumonia has failed in a late-stage trial, the Swiss company said on July 29. Roche launched the 452-patient trial in March as it joined other pharmaceutical companies seeking to re-purpose existing medicines to fight the pandemic. The…

Filed under:Drug Updates Tagged with:COVID-19Rochetocilizumab

  • 1
  • 2
  • 3
  • …
  • 26
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2000-2023 American College of Rheumatology. All rights reserved. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences